ASCO Treatment Framework for Management of Mantle Cell Lymphoma Calls for Individualized, Risk-Adapted Therapy

Why It Matters

The framework aligns treatment intensity with molecular risk, improving outcomes while sparing patients unnecessary toxicity and costly transplant procedures.

Key Takeaways

• MIPI and MIPI‑c remain core for MCL risk stratification.
• Ibrutinib plus chemo improves 3‑yr failure‑free survival to ~87%.
• ASCT shows no survival advantage over optimized maintenance in fit patients.
• BTK‑inhibitor triplets achieve >90% response in TP53‑mutated MCL.
• Non‑covalent BTK inhibitor pirtobrutinib approved for BTK‑refractory disease.

Pulse Analysis

Risk stratification in mantle‑cell lymphoma has moved beyond basic clinical scores to a nuanced molecular portrait. The MIPI and its Ki‑67‑enhanced variant (MIPI‑c) remain foundational, but routine assessment of TP53 mutations and MRD by next‑generation sequencing now guides therapeutic intensity. This granular approach helps clinicians justify tailored regimens to payors, addressing prior‑authorization hurdles that often overlook individual disease biology.

Frontline therapy is being reshaped by the integration of BTK inhibition. The TRIANGLE trial demonstrated that adding ibrutinib to alternating R‑CHOP/R‑DHAP lifts three‑year failure‑free survival to about 87%, while eliminating the need for autologous stem‑cell transplant in most fit patients. By reducing transplant‑related toxicity and associated hospital costs, the new paradigm promises both clinical and economic benefits, prompting institutions to revisit long‑standing transplant pathways.

For older or transplant‑ineligible patients, BTK‑inhibitor‑based doublets and triplets—particularly those pairing a second‑generation BTK inhibitor with venetoclax—deliver response rates exceeding 90% and offer fixed‑duration options that may curb long‑term drug spend. The emergence of non‑covalent agents like pirtobrutinib expands the arsenal for BTK‑refractory disease, positioning oral small‑molecule therapy as a more accessible alternative to CAR‑T or bispecific antibodies. As these regimens gain regulatory approval, pharmaceutical pipelines and payer formularies will need to adapt to a rapidly diversifying MCL treatment landscape.